JP2020533966A - Ｍｙｃｅｌｉｏｐｈｔｈｏｒａ ｔｈｅｒｍｏｐｈｉｌａ中でのフルワクチンの産生 - Google Patents

Ｍｙｃｅｌｉｏｐｈｔｈｏｒａ ｔｈｅｒｍｏｐｈｉｌａ中でのフルワクチンの産生 Download PDF

Info

Publication number
JP2020533966A
JP2020533966A JP2020510102A JP2020510102A JP2020533966A JP 2020533966 A JP2020533966 A JP 2020533966A JP 2020510102 A JP2020510102 A JP 2020510102A JP 2020510102 A JP2020510102 A JP 2020510102A JP 2020533966 A JP2020533966 A JP 2020533966A
Authority
JP
Japan
Prior art keywords
influenza virus
influenza
surface protein
protein
virus surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020510102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533966A5 (enExample
Inventor
エマルファーブ，マーク
コーネリス フルウールト，テウニス
コーネリス フルウールト，テウニス
アール． アルフェニト，マーク
アール． アルフェニト，マーク
ベアー，マーク
レガステロイ，イザベル
カゼック，マリー−ピエール
バーナード，マリー−クロティルダ
デュバイユ，ジーン
ケンジンガー，リチャード
Original Assignee
ダイアディク インターナショナル インコーポレイテッド
ダイアディク インターナショナル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアディク インターナショナル インコーポレイテッド, ダイアディク インターナショナル インコーポレイテッド filed Critical ダイアディク インターナショナル インコーポレイテッド
Publication of JP2020533966A publication Critical patent/JP2020533966A/ja
Publication of JP2020533966A5 publication Critical patent/JP2020533966A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020510102A 2017-08-21 2018-08-09 Ｍｙｃｅｌｉｏｐｈｔｈｏｒａ ｔｈｅｒｍｏｐｈｉｌａ中でのフルワクチンの産生 Pending JP2020533966A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547885P 2017-08-21 2017-08-21
US62/547,885 2017-08-21
PCT/IB2018/056003 WO2019038623A1 (en) 2017-08-21 2018-08-09 PRODUCTION OF AN INFLUENZA VACCINE IN MYCELIOPHTHORA THERMOPHILA

Publications (2)

Publication Number Publication Date
JP2020533966A true JP2020533966A (ja) 2020-11-26
JP2020533966A5 JP2020533966A5 (enExample) 2021-09-16

Family

ID=65438455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020510102A Pending JP2020533966A (ja) 2017-08-21 2018-08-09 Ｍｙｃｅｌｉｏｐｈｔｈｏｒａ ｔｈｅｒｍｏｐｈｉｌａ中でのフルワクチンの産生

Country Status (9)

Country Link
US (2) US11738080B2 (enExample)
EP (1) EP3672630A4 (enExample)
JP (1) JP2020533966A (enExample)
KR (1) KR20200090143A (enExample)
CN (1) CN111315408A (enExample)
AU (1) AU2018319501A1 (enExample)
CA (1) CA3073646A1 (enExample)
IL (1) IL272568A (enExample)
WO (1) WO2019038623A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229483A1 (en) * 2020-05-14 2021-11-18 Dyadic International (Usa), Inc. Modified filamentous fungi for production of exogenous proteins
CN117377752A (zh) * 2021-03-11 2024-01-09 二进国际(美国)有限公司 用于生产具有减少的或不含n-连接的糖基化的外源蛋白的遗传修饰的丝状真菌
WO2023225646A1 (en) 2022-05-20 2023-11-23 Phibro Animal Health Corporation Using fungal constructs to produce viral protein antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504012A (ja) * 2000-04-13 2004-02-12 エマルフアーブ，マーク・アーロン 糸状菌の分野における新規発現調節配列および発現産物
WO2016097369A1 (en) * 2014-12-19 2016-06-23 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3621995B2 (ja) 1994-05-20 2005-02-23 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 赤血球凝集素のアシル化／パルミチル化を抑制する抗ウイルス剤を用いるインフルエンザウイルス感染の治療
AU771539C (en) * 1998-10-06 2005-01-13 Dyadic International (Usa), Inc. Transformation system in the field of filamentous fungal hosts
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
EP1799261B1 (en) * 2004-10-15 2012-12-05 Intrexon Corporation Methods and compositions for combinatoral-based production of multivalent recombinant antigens
US8680252B2 (en) * 2006-12-10 2014-03-25 Dyadic International (Usa), Inc. Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
WO2008073490A1 (en) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification of influenza viral antigens
CA2755417C (en) 2009-03-16 2018-11-13 Dyadic Nederland B.V. New fungal production system
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
WO2010150982A2 (ko) 2009-06-23 2010-12-29 한밭대학교 산학협력단 안전성이 뛰어난 인플루엔자 바이러스 백신용 재조합 헤마글루티닌 단백질 및 이를 함유하는 생분해성 ｐｌｇａ 미립자의 제조 방법
CN102985107A (zh) 2010-01-24 2013-03-20 生物模仿公司 免疫性流感成分
BR112014022506A2 (pt) * 2012-03-12 2018-11-06 Codexis Inc variantes de cbh1a
US20130315955A1 (en) 2012-04-13 2013-11-28 Protein Sciences Corporation Stability and potency of hemagglutinin
EP3384002A1 (en) 2015-12-02 2018-10-10 Basf Se Method of producing proteins in filamentous fungi with decreased clr2 activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504012A (ja) * 2000-04-13 2004-02-12 エマルフアーブ，マーク・アーロン 糸状菌の分野における新規発現調節配列および発現産物
WO2016097369A1 (en) * 2014-12-19 2016-06-23 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
上原記念生命科学財団研究報告集[ONLINE]，2015, VOL.29, P.1-9, 139.インフルエンザウイルス粒子形成スイ, JPN6022024102, ISSN: 0004970890 *

Also Published As

Publication number Publication date
WO2019038623A1 (en) 2019-02-28
US11738080B2 (en) 2023-08-29
EP3672630A4 (en) 2021-06-02
US20200215183A1 (en) 2020-07-09
US20230346913A1 (en) 2023-11-02
KR20200090143A (ko) 2020-07-28
EP3672630A1 (en) 2020-07-01
CA3073646A1 (en) 2019-02-28
CN111315408A (zh) 2020-06-19
AU2018319501A1 (en) 2020-04-02
IL272568A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
KR101541330B1 (ko) 식물에서 생산된 헤마글루티닌을 포함하는 인플루엔자 바이러스-유사 입자(ＶＬＰｓ)
US20230346913A1 (en) Production of flu vaccine in myceliophthora thermophila
US9546375B2 (en) Influenza virus immunizing epitope
US9795666B2 (en) High-yield transgenic mammalian expression system for generating virus-like particles
RU2705555C2 (ru) Получение вирусоподобных частиц вируса гриппа в растениях
CA2774640C (en) Virus like particles comprising target proteins fused to plant viral coat proteins
EA034733B1 (ru) Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
EP3160501B1 (en) Influenza virus hemagglutinin protein as a vaccine antigen
CN110272473A (zh) 甲型流感通用型病毒样颗粒及其制备方法和应用
MX2014003776A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
AU2017225820B2 (en) Novel influenza antigens
CN108348596B (zh) 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒
Qian et al. Secretion of truncated recombinant rabies virus glycoprotein with preserved antigenic properties using a co-expression system in Hansenula polymorpha
US20240335525A1 (en) Truncated influenza neuraminidase and methods of using the same
EP3083660A1 (en) Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine
CN116589596A (zh) 甲型流感na多肽广谱免疫原及其序贯免疫方法
AU2015202195B2 (en) New influenza virus immunizing epitope
RU2569195C9 (ru) Химерные вирусоподобные частицы, содержащие гемагглютинин, сходные с частицами вируса гриппа
HK1259067B (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
HK1156969B (en) New influenza virus immunizing epitope

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230124